Previous 10 | Next 10 |
BOSTON, June 01, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced Axel Bolte, MSc, MBA, the company’s co-founder, president...
Jefferies has initiated Inozyme (INZY) at hold saying proof-of-concept data on lead asset INZ-701 for two rare abnormal mineralization disorders. The firm has a $5 price target (~25% upside based on Wednesday's closing price). For further details see: Inozyme initiated at hold at Jeffer...
Inozyme Pharma press release (NASDAQ:INZY): Q1 GAAP EPS of -$0.71 beats by $0.11. Cash, cash equivalents, and investments were $97.8 million as of March 31, 2022. For further details see: Inozyme Pharma GAAP EPS of -$0.71 beats by $0.11
– Recently reported positive preliminary biomarker and safety data from ongoing Phase 1/2 clinical trial of INZ-701 in ENPP1 Deficiency – – Preliminary biomarker and safety data from ongoing Phase 1/2 trial of INZ-701 in ABCC6 Deficiency on track for the secon...
Gainers: Cyngn (CYN) +70%. Sky Harbour Group (SKYH) +28%. Redbox Entertainment (RDBX) +25%. Wrap Technologies (WRAP) +18%. Inozyme Pharma (INZY) +16%. MedAvail Holdings (MDVL) +14%. Red Cat Holdings (OTCQB:RCAT) +13%. Pulse Biosciences (PLSE) +12%. United Airlines Holdings (UAL) +11%. Alpha T...
Shares of Inozyme Pharma surged 17% on Thursday after SEC filings indicated stock purchases by company executives and a director. On April 19, CEO Axel Bolte bought 67,750 shares at a price of $3.69 for a purchase price of ~250K. On the same date, CFO Sanjay Subramanian and COO Henr...
Gainers: Inozyme Pharma (INZY) +15%. Clarus Therapeutics (CRXT) +10%. MedAvail (MDVL) +5%. Syros Pharmaceuticals (SYRS) +5%. Magenta Therapeutics (MGTA) +4%. Losers: AlloVir (ALVR) -10%. Rite Aid (RAD) -9%. Windtree Therapeutics (WINT) -7...
Gainers: Lexaria Bioscience (LEXX) +23%. Rite Aid (RAD) +14%. Inozyme Pharma (INZY) +12%. Finch Therapeutics (FNCH) +11%. Valneva (VALN) +9%. Losers: Protagonist Therapeutics (PTGX) -23%. Lixte Biotechnology (LIXT) -10%. Biofrontera (BFRI) ...
Inozyme Pharma (NASDAQ:INZY) has priced offering of 16,276,987 shares of its common stock at $3.69 per share and to certain investors in lieu of common stock, pre-funded warrants to purchase 3,523,013 shares of common stock at $3.6899 per pre-funded warrant, for aggregate gross proceeds of ~$...
BOSTON, April 14, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced the pricing of an underwritten offering of 16,276,987 shares of...
News, Short Squeeze, Breakout and More Instantly...
2024-07-27 20:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
BOSTON, July 02, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal prolifer...
BOSTON, June 21, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferatio...